Lead Product(s): BBT-401
Therapeutic Area: Gastroenterology Product Name: BBT-401
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Bridge Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 15, 2020
BBT-401, the first-in-class Pellino-1 inhibitor for treatment of ulcerative colitis, is currently in Phase II in the US, and BBT-877, an autotaxin inhibitor to treat various fibrosing interstitial lung diseases including idiopathic pulmonary fibrosis (IPF).